John R. Eckardt

3.8k total citations
85 papers, 3.2k citations indexed

About

John R. Eckardt is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John R. Eckardt has authored 85 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 53 papers in Molecular Biology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John R. Eckardt's work include Cancer therapeutics and mechanisms (42 papers), Lung Cancer Research Studies (42 papers) and Neuroendocrine Tumor Research Advances (20 papers). John R. Eckardt is often cited by papers focused on Cancer therapeutics and mechanisms (42 papers), Lung Cancer Research Studies (42 papers) and Neuroendocrine Tumor Research Advances (20 papers). John R. Eckardt collaborates with scholars based in United States, France and United Kingdom. John R. Eckardt's co-authors include Howard A. Burris, Daniel D. Von Hoff, Geoffrey R. Weiss, John G. Kuhn, Susan G. Hilsenbeck, G I Rodriguez, Mace L. Rothenberg, Lon Smith, David Rinaldi and S. Gail Eckhardt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

John R. Eckardt

83 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John R. Eckardt United States	31	2.2k	1.7k	667	649	313	85	3.2k
Agop Y. Bedikian United States	38	3.6k 1.6×	2.6k 1.5×	1.0k 1.5×	373 0.6×	231 0.7×	170	5.8k
Francisco Robert United States	28	1.8k 0.8×	1.1k 0.7×	1.4k 2.1×	338 0.5×	110 0.4×	107	3.2k
L B Grochow United States	32	2.2k 1.0×	1.8k 1.1×	523 0.8×	205 0.3×	153 0.5×	48	3.6k
Paul Noordhuis Netherlands	32	1.7k 0.8×	1.4k 0.8×	506 0.8×	146 0.2×	245 0.8×	82	3.4k
Linda Janisch United States	23	2.1k 1.0×	1.7k 1.0×	738 1.1×	159 0.2×	141 0.5×	68	3.6k
Maja J.A. de Jonge Netherlands	33	1.5k 0.7×	1.7k 1.0×	620 0.9×	115 0.2×	177 0.6×	107	3.1k
S E Sartorius United States	19	1.8k 0.8×	1.0k 0.6×	399 0.6×	115 0.2×	183 0.6×	26	2.4k
Francesco Caponigro Italy	28	2.3k 1.1×	2.0k 1.2×	1.2k 1.9×	172 0.3×	197 0.6×	101	4.6k
M. Fukuoka Japan	35	3.3k 1.5×	1.8k 1.0×	2.7k 4.0×	559 0.9×	83 0.3×	131	4.4k
Lisa A. Hammond United States	31	3.0k 1.4×	1.6k 0.9×	2.0k 3.0×	137 0.2×	344 1.1×	56	4.5k

Countries citing papers authored by John R. Eckardt

Since Specialization

Citations

This map shows the geographic impact of John R. Eckardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Eckardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Eckardt more than expected).

Fields of papers citing papers by John R. Eckardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Eckardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Eckardt. The network helps show where John R. Eckardt may publish in the future.

Co-authorship network of co-authors of John R. Eckardt

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Eckardt. A scholar is included among the top collaborators of John R. Eckardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Eckardt. John R. Eckardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cashen, Amanda F., Mark Juckett, Mark R. Litzow, et al.. (2011). Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Annals of Hematology. 91(1). 33–38. 53 indexed citations

Arnold, Susanne M., John J. Rinehart, Eleftheria Tsakalozou, et al.. (2010). A Phase I Study of 7- t -Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies. Clinical Cancer Research. 16(2). 673–680. 23 indexed citations

Novello, Silvia, Francisco Pimentel, Jean‐Yves Douillard, et al.. (2010). Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(10). 1602–1608. 10 indexed citations

Eckardt, John R., Joachim von Pawel, Jean-Louis Pujol, et al.. (2007). Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(15). 2086–2092. 274 indexed citations

Belani, Chandra P. & John R. Eckardt. (2004). Development of docetaxel inadvanced non-small-cell lung cancer. Lung Cancer. 46. S3–S11. 19 indexed citations

Thatcher, Nick, John R. Eckardt, & Mark A. Green. (2003). Options for first- and second-line therapy in small cell lung cancer — a workshop discussion. Lung Cancer. 41. S37–S41. 13 indexed citations

Douillard, Jean‐Yves, John R. Eckardt, & Giorgio V. Scagliotti. (2002). Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer. 38. 21–28. 23 indexed citations

Eckhardt, S. Gail, Jinee Rizzo, Kevin Sweeney, et al.. (1999). Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 17(4). 1095–1095. 55 indexed citations

Rodriguez, Gladys, John G. Kuhn, Geoffrey R. Weiss, et al.. (1998). A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Investigational New Drugs. 16(1). 57–67. 2 indexed citations

10.

Creemers, G.J., C J Gerrits, John R. Eckardt, et al.. (1997). Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.. Journal of Clinical Oncology. 15(3). 1087–1093. 66 indexed citations

11.

Raymond, Éric, Howard A. Burris, Eric K. Rowinsky, et al.. (1997). Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Annals of Oncology. 8(10). 1003–1008. 31 indexed citations

12.

Eckardt, John R.. (1997). Antitumor activity of docetaxel. American Journal of Health-System Pharmacy. 54(suppl_2). S2–S6. 18 indexed citations

13.

Weiss, Geoffrey R., Carl deMoor, David Rinaldi, et al.. (1996). A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer. Anti-Cancer Drugs. 7(4). 402–409. 3 indexed citations

14.

Eckhardt, S. Gail, Howard A. Burris, John R. Eckardt, et al.. (1996). A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Annals of Oncology. 7(5). 491–496. 34 indexed citations

15.

Weiss, Geoffrey R., John G. Kuhn, Jinee Rizzo, et al.. (1995). A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 35(5). 397–402. 12 indexed citations

16.

Rinaldi, David, Howard A. Burris, F. Andrew Dorr, et al.. (1995). Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.. Journal of Clinical Oncology. 13(11). 2842–2850. 132 indexed citations

17.

Eckardt, John R., et al.. (1994). Activity of Intoplicine (RP60475), a New DNA Topoisomerase I and II Inhibitor, Against Human Tumor Colony-Forming Units In Vitro. JNCI Journal of the National Cancer Institute. 86(1). 30–33. 10 indexed citations

18.

Fuqua, Suzanne A.W., Steffi Oesterreich, Susan G. Hilsenbeck, et al.. (1994). Heat shock proteins and drug resistance. Breast Cancer Research and Treatment. 32(1). 67–71. 98 indexed citations

19.

Burris, Howard A., Ahmad Awada, John G. Kuhn, et al.. (1994). Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-Cancer Drugs. 5(4). 394–402. 40 indexed citations

20.

Burris, Howard A., John G. Kuhn, Lee Smith, et al.. (1993). Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.. Journal of Clinical Oncology. 11(5). 950–958. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact